Peptide Synthesis Market by Product (Reagents, Synthesizers, and Chromatography); Therapeutic Area (Cardiovascular Disorder, Cancer, Respiratory Disorder, Metabolic Disorder, Dermatology, and Others); End User (Pharmaceutical and Biotechnological Companies, Contract Research Organizations (CRO\'s), Academic and Research Institutes, and Others), and Geography: Global Market Size Estimates and Forecast (2022-2030)

Code: BMIRE00027070 | Pages: 100 | Industry: Biotechnology | Date: Oct 2022 | Type: Global

The market crossed the US$ 525 million mark in 2022 and is expected to hit US$ 775 million by 2030, recording a CAGR of 7.0% during the forecast period.

The peptide synthesis market has been significantly growing with the use of peptides in pharmaceutical drugs. 

Due to their versatile nature, peptides are gaining traction in various pharmaceutical drugs for managing various diseases, such as cancer, diabetes, obesity, and others. Currently, more than 100 peptide drugs are available on the market and are showing huge adoption rates among patients. The market for peptide synthesis is growing with the growing commercial popularity. For example, Lupron manufactured by Abbvie is a peptide-based medication indicated to treat diseases including prostate cancer and others and had all sales of more than USD 755 million in 2020. In 2021, the reagents segment held the maximum share in the global market mainly due to expanding applications in various therapeutic areas.     

Within the report, the market is segmented into product, therapeutic area, end-user, and geography. By product, the market is segmented into reagents, synthesizers, and chromatography. By therapeutic area, the market is categorized into cardiovascular disorder, cancer, respiratory disorder, metabolic disorder, dermatology, and others. Based on end-user, the market is divided into pharmaceutical and biotechnological companies, research institutes, and others. Geographically, the market is sub segmented into North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa.

Get more information on this report :

The development of personalized medicine will provide future opportunity

Peptides are unique drug components. The peptides have a critical role in a wide range of biological functions and, therefore, are utilized in a wide range of diseases. The peptides offer a wide range of characteristics such as vast chemical space, high specificity, physical activity, relative ease of synthesis, ready availability, and low toxicity. They are thus increasingly considered potential active pharmaceutical ingredients in drug production. These treat several diseases, including cancer, cardiovascular disease, respiratory problems, and others.

In the last years, there has been huge interest in developing personalized therapy, ensuring high safety and better patient care. Personalized proteomics or proteomic profiling is the next major step in personalized medicine. Rising investments in personalized medicine can primarily be attributed to the growing demand for advanced treatments with minimal side effects and the increasing incidences of disorders including cancer, cardiovascular diseases, and others. Such advancements in the personalized medicine field will offer growth opportunities for players in the peptide synthesis market.

The increasing use of peptides in the pharmaceutical sector is one of the major factors accelerating market growth.

The rising incidences of chronic diseases and the associated benefits of peptides in their management drive the market's growth. For example, as per the International Diabetes Federation statistics published in 2021, 537 million adults (20-79 years) were living with diabetes globally. Moreover, peptide-based approaches were also being used in the management of COVID-19. A peptide-based vaccine, CoVac-1 consists of SARS-CoV-2 T-cell epitopes derivative from several viral proteins, along with the Toll-like receptor 1/2 agonist XS15 emulsified in Montanide ISA51 VG. The vaccine aims to induce strong SARS-CoV-2 T-cell immunity to fight off COVID-19. These developments have enhanced the demand for materials and machinery for the manufacture of peptides.

Recent strategic developments in the peptide synthesis market

The cell culture market has undergone several significant developments, and a few of these have been mentioned below:

  • In August 2021, Bachem Holding AG entered into collaboration with Novo Nordisk to design a greener technology for solid-phase peptide synthesis (SPPS), under which two studies were conducted to find solvent alternatives to replace the reprotoxic N, N-dimethylformamide (DMF), dichloromethane (DCM), and N-methyl-2-pyrrolidone (NMP).
  • In February 2021, Thermo Fisher Scientific(US) introduced novel capillary chromatography columns for proteomics, clinical peptides, and biopharmaceutical research laboratories performing high throughput, high-performance liquid chromatography (HPLC), or liquid chromatography-mass spectrometry (LC-MS) analysis.

Several players drive the peptide synthesis market by implementing strategic activities such as investments, new launches, mergers & acquisitions, and partnerships. Bachem Holding AG, Thermo Fisher Scientific, Merck KGaA, GenScript Biotech Corporation, Kaneka Corporation, and Biotage AB are among the prominent players operating in the market.

Target audience for the report:

  • Drug developing companies
  • Contract development and manufacturing organization,
  • Drug discovery-related associations, organizations, forums, and alliances
  • Government bodies, such as regulating authorities and policymakers
  • Venture capitalists, private equity firms, and start-up companies
  • Drug distributors and sales firms
  • End users of drug discovery
  • Research institutes, organizations, and consulting companies

Scope of the report:

In this report, the market has been segmented on the basis of:

  • Product:
    • Reagents
    • Synthesizers
    • Chromatography
  • Therapeutic area:
    • Cardiovascular  disorder
    • Cancer
    • Respiratory disorder
    • Metabolic disorder
    • Dermatology
    • Others
  • End User:
    • Pharmaceutical and Biotechnological companies
    • Contract research organizations
    • Academic and research institutes
    • Others
  • Region
    • North America
    • Europe
    • Asia Pacific (APAC)
    • South & Central America
    • Middle East & Africa
  • Companies profiled
    • Merck KGaA
    • Aapptec
    • CEM Corporation
    • Pfizer Inc.
    • Sanofi
    • GenScript
    • Biotage
    • Eli Lilly and Company
    • Teva Pharmaceutical
    • AstraZeneca Plc

The List of Companies
- Merck KGaA
- Aapptec
- CEM Corporation
- Pfizer Inc.
- Sanofi
- GenScript
- Biotage
- Eli Lilly and Company
- Teva Pharmaceutical
- AstraZeneca Plc

Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$1500
Site License
$2500
Enterprise License
$3500